Subtopic Deep Dive
Androgen Deprivation Therapy Resistance
Research Guide
What is Androgen Deprivation Therapy Resistance?
Androgen Deprivation Therapy Resistance refers to the molecular and clinical mechanisms enabling castration-resistant prostate cancer (CRPC) progression despite castrate testosterone levels.
CRPC arises after initial ADT response due to AR variants like AR-V7, intratumoral androgen synthesis, and lineage plasticity. Key studies identify AR-V7 in circulating tumor cells predicting resistance to enzalutamide and abiraterone (Antonarakis et al., 2014, 2633 citations). Over 10 listed papers from 2008-2019 detail trial designs and therapies, with Scher et al. (2012) reporting enzalutamide survival benefits (4508 citations).
Why It Matters
CRPC accounts for most prostate cancer deaths, necessitating therapies targeting resistance pathways. Enzalutamide extended survival in post-chemotherapy CRPC patients (Scher et al., 2012, 4508 citations), while abiraterone delayed progression pre-chemotherapy (Ryan et al., 2012, 2747 citations). AR-V7 detection guides treatment selection by predicting novel hormone therapy failure (Antonarakis et al., 2014, 2633 citations), informing trials like those recommended by Scher et al. (2008, 2209 citations). Watson et al. (2015, 1483 citations) outline mechanisms driving combination strategies to overcome resistance.
Key Research Challenges
AR Splice Variant Detection
AR-V7 in circulating tumor cells confers resistance to enzalutamide and abiraterone, requiring liquid biopsy assays for clinical use. Prospective validation remains needed despite initial findings (Antonarakis et al., 2014, 2633 citations). Scalable detection lags behind therapeutic demand.
Intratumoral Androgen Synthesis
CRPC tumors maintain androgens via upregulated synthesis enzymes despite ADT, fueling growth. Targeting this demands combination therapies beyond single agents (Montgomery et al., 2008, 1402 citations). Mechanisms vary, complicating uniform treatment.
Lineage Plasticity Mechanisms
Neuroendocrine transdifferentiation and plasticity evade AR dependence, emerging post-ADT. Emerging resistance pathways challenge AR-focused inhibitors (Watson et al., 2015, 1483 citations). Trial endpoints must adapt to these phenotypes (Scher et al., 2016, 1507 citations).
Essential Papers
Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
Howard I. Scher, Karim Fizazi, Fred Saad et al. · 2012 · New England Journal of Medicine · 4.5K citations
Enzalutamide significantly prolonged the survival of men with metastatic castration-resistant prostate cancer after chemotherapy. (Funded by Medivation and Astellas Pharma Global Development; AFFIR...
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
Charles J. Ryan, Matthew R. Smith, Johann S. de Bono et al. · 2012 · New England Journal of Medicine · 2.7K citations
Abiraterone improved radiographic progression-free survival, showed a trend toward improved overall survival, and significantly delayed clinical decline and initiation of chemotherapy in patients w...
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
Christopher J. Sweeney, Yu‐Hui Chen, Michael A. Carducci et al. · 2015 · New England Journal of Medicine · 2.7K citations
Six cycles of docetaxel at the beginning of ADT for metastatic prostate cancer resulted in significantly longer overall survival than that with ADT alone. (Funded by the National Cancer Institute a...
AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer
Emmanuel S. Antonarakis, Changxue Lu, Hao Wang et al. · 2014 · New England Journal of Medicine · 2.6K citations
Detection of AR-V7 in circulating tumor cells from patients with castration-resistant prostate cancer may be associated with resistance to enzalutamide and abiraterone. These findings require large...
Epidemiology of Prostate Cancer
Prashanth Rawla · 2019 · World Journal of Oncology · 2.6K citations
Prostate cancer is the second most frequent cancer diagnosis made in men and the fifth leading cause of death worldwide. Prostate cancer may be asymptomatic at the early stage and often has an indo...
Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group
Howard I. Scher, Susan Halabi, Ian F. Tannock et al. · 2008 · Journal of Clinical Oncology · 2.2K citations
Purpose To update eligibility and outcome measures in trials that evaluate systemic treatment for patients with progressive prostate cancer and castrate levels of testosterone. Methods A committee ...
Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer
Karim Fizazi, NamPhuong Tran, Luis Fein et al. · 2017 · New England Journal of Medicine · 2.1K citations
The addition of abiraterone acetate and prednisone to androgen-deprivation therapy significantly increased overall survival and radiographic progression-free survival in men with newly diagnosed, m...
Reading Guide
Foundational Papers
Start with Scher et al. (2012, 4508 citations) for enzalutamide efficacy in CRPC, Scher et al. (2008, 2209 citations) for trial designs, and Montgomery et al. (2008) for intratumoral androgens.
Recent Advances
Study Antonarakis et al. (2014, 2633 citations) for AR-V7, Fizazi et al. (2017, 2110 citations) for abiraterone in CSPC, and Watson et al. (2015, 1483 citations) for resistance mechanisms.
Core Methods
AR-V7 RT-PCR in CTCs (Antonarakis 2014); radiographic PFS/OS endpoints (Scher 2008, 2016); intratumoral androgen assays via mass spectrometry (Montgomery 2008).
How PapersFlow Helps You Research Androgen Deprivation Therapy Resistance
Discover & Search
Research Agent uses citationGraph on Scher et al. (2012, 4508 citations) to map CRPC trial networks, then findSimilarPapers uncovers AR-V7 resistance studies like Antonarakis et al. (2014). exaSearch queries 'AR-V7 circulating tumor cells enzalutamide resistance' for 250M+ OpenAlex papers, filtering high-citation mechanistic works.
Analyze & Verify
Analysis Agent applies readPaperContent to Antonarakis et al. (2014) for AR-V7 assay details, then verifyResponse (CoVe) cross-checks resistance claims across Scher (2012) and Watson (2015). runPythonAnalysis processes survival data from Ryan et al. (2012) with pandas for hazard ratios; GRADE grading scores enzalutamide evidence as high-quality.
Synthesize & Write
Synthesis Agent detects gaps in AR-independent resistance via contradiction flagging between ADT trials (Scher 2008, 2016). Writing Agent uses latexEditText for CRPC mechanism reviews, latexSyncCitations for 10+ papers, and latexCompile for publication-ready manuscripts; exportMermaid diagrams AR-V7 signaling pathways.
Use Cases
"Extract survival curves from enzalutamide CRPC trials and plot Kaplan-Meier with Python."
Research Agent → searchPapers 'enzalutamide Scher 2012' → Analysis Agent → readPaperContent → runPythonAnalysis (pandas/matplotlib for HR/confidence intervals) → matplotlib plot of OS/PFS curves.
"Write LaTeX review on AR-V7 resistance mechanisms with citations."
Synthesis Agent → gap detection on Antonarakis (2014)/Watson (2015) → Writing Agent → latexEditText (draft sections) → latexSyncCitations (10 papers) → latexCompile → PDF with AR pathway figure.
"Find GitHub repos analyzing AR-V7 expression data from CRPC papers."
Research Agent → searchPapers 'AR-V7 prostate cancer datasets' → paperExtractUrls → paperFindGithubRepo → githubRepoInspect → exportCsv of analysis scripts for resistance modeling.
Automated Workflows
Deep Research workflow scans 50+ CRPC papers via searchPapers → citationGraph → structured report on resistance mechanisms from Scher (2012) to Fizazi (2017). DeepScan's 7-step chain analyzes Antonarakis (2014) with CoVe checkpoints and GRADE for AR-V7 evidence. Theorizer generates hypotheses on lineage plasticity by synthesizing Watson (2015) mechanisms with trial data.
Frequently Asked Questions
What defines Androgen Deprivation Therapy Resistance?
ADT resistance is CRPC progression with castrate testosterone levels, driven by AR variants and plasticity (Antonarakis et al., 2014).
What are key methods to study resistance?
Liquid biopsies detect AR-V7 in CTCs; trial endpoints include rPFS/OS per Scher et al. (2008, 2016 recommendations).
What are seminal papers?
Scher et al. (2012, 4508 citations) on enzalutamide; Antonarakis et al. (2014, 2633 citations) on AR-V7; Watson et al. (2015, 1483 citations) on mechanisms.
What open problems exist?
Prospective AR-V7 validation, targeting lineage plasticity, and adaptive trial designs for heterogeneous CRPC (Scher et al., 2016).
Research Prostate Cancer Diagnosis and Treatment with AI
PapersFlow provides specialized AI tools for your field researchers. Here are the most relevant for this topic:
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Deep Research Reports
Multi-source evidence synthesis with counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
AI Academic Writing
Write research papers with AI assistance and LaTeX support
Start Researching Androgen Deprivation Therapy Resistance with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.